Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus valganciclovir for relapsed or refractory malignant glioma
ChiCTR-OIN-17012863Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valganciclovir in malignant glioma, glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Renji Hospital. Primary endpoints: partial or complete remission rate and survival. Started Oct 2017; status: recruiting.
02
Drugs
valganciclovir
03
Conditions
malignant gliomaglioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on ChiCTR-OIN-17012863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-17012863.